[Ip-health] ADVISORY - Tufts CSDD to Disclose Cost of Developing a New Drug at Nov. 18 Briefing

Thiru Balasubramaniam thiru at keionline.org
Mon Nov 17 09:37:07 PST 2014


http://www.marketwired.com/press-release/advisory-tufts-csdd-to-disclose-cost-of-developing-a-new-drug-at-nov-18-briefing-1966111.htm

The Tufts Center for Drug Development will present the results of its new
study on the costs of drug development at 10 AM EST on 18 November 2014.

Please see below for details.

Thiru

--

November 10, 2014 09:00 ET
ADVISORY - Tufts CSDD to Disclose Cost of Developing a New Drug at Nov. 18
Briefing

BOSTON, MA--(Marketwired - Nov 10, 2014) -


*FROM:*Tufts Center for the Study of Drug Development, Tufts University,
Boston, Mass.


*WHAT:*Press briefing at which Tufts CSDD will present results of its
latest study, updating the total average cost of developing a new
prescription drug.

The Tufts CSDD estimate is the number that industry, governments, payers,
and others depend on for strategic planning and formulation of prescription
drug policy.


*PRESS:*Invited to attend the briefing. Please register in advance by
emailing Sandra.Peters at tufts.edu


*WHEN:*Tuesday, Nov. 18, 2014
10:00 - 11:00 a.m., Eastern time


*WHERE:*Tufts University School of Medicine
Sackler School of Graduate Biomedical Sciences
145 Harrison Avenue, Sackler 114 East, First Floor, Boston

Nearest MBTA stop: Tufts Medical Center on the MBTA Orange line.

Parking available at Tufts Medical Center Garage at 274 Tremont Street,
Boston, and Pilgrim Parking Corporation at 40 Beach Street, Boston.


*LIVE WEBCAST:*The briefing will be webcast live. To access it, click on
http://csdd.tufts.edu/news/complete_story/cost_study_press_event_webcast
<http://ctt.marketwire.com/?release=1157409&id=4941310&type=1&url=http%3a%2f%2fcsdd.tufts.edu%2fnews%2fcomplete_story%2fcost_study_press_event_webcast>
.


*WHY:*What it costs to develop and win marketing approval for a new
prescription drug is of strong and growing interest to a broad range of
constituencies: drug developers and their research partners, investors,
payers, legislators, patient advocacy groups, health care policy
analysts/makers, academic researchers, and others working with the
research-based biopharmaceutical industry and/or concerned with the
economics of drug development.

The Tufts CSDD estimate is based on rigorous analysis of real-world data
and is acknowledged to be the objective standard.


*FINDINGS:*News release summarizing key findings will be made available at
10:30 a.m. on Nov. 18.


*SPEAKERS:*Dr. Joseph A. DiMasi, director of economic analysis at Tufts
CSDD and principal investigator for the study.

Dr. Kenneth I Kaitin, director of Tufts CSDD.


CONTACT INFORMATION

   -


*CONTACTS: *Sandra Peters
   Tufts Center for the Study of Drug Development
   Sandra.Peters at tufts.edu
   Tel: 617-636-2185

   Peter Lowy
   Business Communication Strategies
   lowy at bus-com.com
   Tel: 617-734-9980



More information about the Ip-health mailing list